| Trial | Common mutations | Del19 | Exon 21 | Uncommon mutation | ||||||||
| Patients treated with TKI n | Median PFS months | HR (95% CI), p-value | Patients treated with TKI n | PFS months | HR (95% CI), p-value | Patients treated with TKI n | PFS months | HR (95% CI), p-value | Patients treated with TKI n | PFS months | HR (95% CI), p-value | |
| NEJ002 [12, 23] | 107 | NR | NR | 58 | 11.5 | NR | 49 | 10.8 | NR | 7 | NR | NR |
| WJTOG3405 [13, 25] | 51 (stage IIIb/IV subgroup) | 8.4 | 0.33 (0.21–0.54), p<0.0001 | NR | NR | NR | NR | NR | NR | NA | NA | NA |
| IPASS [8, 14] | 130 | NR | NR | 66 | 11.0 | 0.38 (0.26–0.56), p = NR | 64 | 9.2 | 0.55 (0.35–0.87), p = NR | 8 | NR | NR |
| EURTAC [9] | 86 | 9.7 | 0.37 (0.25–0.54), p<0.0001 | 57 | 11.0 | 0.3 (0.18–0.50), p<0.0001 | 29 | 8.4 | 0.55 (0.29–1.02), p = 0.0539 | NA | NA | NA |
| LUX-Lung 3 [15] | 204 | 13.6 | 0.47 (0.34–0.65), p = 0.001 | 113 | 13.7 | 0.28 (0.18–0.44), p = 0.01 | 91 | 10.8 | 0.73 (0.46–1.17), p = 0.01 | 26 | 2.8 | |
| OPTIMAL [10] | 82 | 13.1 | 0.16 (0.10–0.26), p<0.0001 | 43 | 15.3 | 0.13 (0.07–0.25), p = NR | 39 | 12.5 | 0.26 (0.14–0.49), p = NR | NA | NA | NA |
| LUX-Lung 6 [16] | 216 | 13.7 | 0.25 (0.18–0.35) | 124 | 13.7 | 0.20 (0.13–0.33), p = NR | 92 | 9.6 | 0.32 (0.19–0.52), p = NR | 26 | 0.55 (0.22–1.43) | |
| ENSURE [17] | 110 | 11.0 | 0.34 (0.22–0.51), p<0.0001 | NR | 11.1 | 0.20 (0.11–0.37), p = NR | NR | 8.3 | 0.57 (0.31–1.05), p = NR | NA | NA | NA |
All data are from investigator assessment, except LUX-Lung 3 which is from independent review. NEJ002: North East Japan 002; WJTOG: West Japan Thoracic Oncology Group; IPASS: Iressa Pan-Asia Study; EURTAC: European Randomised Trial of Tarceva versus Chemotherapy; TKI: tyrosine kinase inhibitor; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; NR; not reported.